Its exudative form, neovascular age-related macular degeneration (nAMD), characterized by the development of macular neovascularization (MNV), requires chronic anti–vascular endothelial growth factor (anti-VEGF) therapy; however, both anatomical and functional responses show substantial inter-individual variability [2,3,4,5]. This evidence concerns the gene VEGFA and wet macular degeneration.